{"pmid":32251794,"title":"Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?","text":["Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO.","Int J Infect Dis","Hong, Xiaoyang","Xiong, Jing","Feng, Zhichun","Shi, Yuan","32251794"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO."],"journal":"Int J Infect Dis","authors":["Hong, Xiaoyang","Xiong, Jing","Feng, Zhichun","Shi, Yuan"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251794","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijid.2020.03.058","keywords":["acute respiratory distress syndrome","coronavirus disease 19","extracorporeal membrane oxygenation","respiratory failure"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352136203763712,"score":7.6679378,"similar":[{"pmid":32203711,"pmcid":"PMC7102637","title":"Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","text":["Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality.","Lancet Respir Med","Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran","32203711"],"abstract":["WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality."],"journal":"Lancet Respir Med","authors":["Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203711","week":"202013|Mar 23 - Mar 29","doi":"10.1016/S2213-2600(20)30121-1","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1663352133666209792,"score":537.1148},{"pmid":32243266,"title":"Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.","text":["Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.","Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear. Eight COVID-19 patients have received ECMO support in Shanghai with 7 with VV ECMO support and 1 VA ECMO during cardiopulmonary resuscitation. As of March 25, 2020, 4 patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40 days and 47 days support respectively, but remain on mechanical ventilation. One patient is still on VV ECMO with mechanical ventilation.The PaO2/FiO2 ratio before ECMO initiation were between 54 to 76 and all were well below 100. The duration of mechanical ventilation before ECMO ranged from 4-21 days. Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 to 47 days. In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes. ECMO support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise.","ASAIO J","Li, Xin","Guo, Zhen","Li, Bailing","Zhang, Xiaolin","Tian, Rui","Wu, Wei","Zhang, Zhongwei","Lu, Yunfei","Chen, Nan","Clifford, Sean P","Huang, Jiapeng","32243266"],"abstract":["Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear. Eight COVID-19 patients have received ECMO support in Shanghai with 7 with VV ECMO support and 1 VA ECMO during cardiopulmonary resuscitation. As of March 25, 2020, 4 patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40 days and 47 days support respectively, but remain on mechanical ventilation. One patient is still on VV ECMO with mechanical ventilation.The PaO2/FiO2 ratio before ECMO initiation were between 54 to 76 and all were well below 100. The duration of mechanical ventilation before ECMO ranged from 4-21 days. Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 to 47 days. In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes. ECMO support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise."],"journal":"ASAIO J","authors":["Li, Xin","Guo, Zhen","Li, Bailing","Zhang, Xiaolin","Tian, Rui","Wu, Wei","Zhang, Zhongwei","Lu, Yunfei","Chen, Nan","Clifford, Sean P","Huang, Jiapeng"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243266","week":"202014|Mar 30 - Apr 05","doi":"10.1097/MAT.0000000000001172","source":"PubMed","locations":["Shanghai","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352135763361795,"score":527.1706},{"pmid":32035430,"title":"[Recommendations on extracorporeal life support for critically ill patients with novel coronavirus pneumonia].","text":["[Recommendations on extracorporeal life support for critically ill patients with novel coronavirus pneumonia].","Along with the sharp increase of confirmed cases novel coronavirus infection, more critically ill cases require extracorporeal membrane oxygenation (ECMO) support. Based on the clinical data of novel coronavirus pneumonia (NCP), as well as the dada from previous clinical studies and the recommendations from the Extracorporeal Life Support Organization (ELSO), the committee board of the Chinese Society of Extracorporeal Life Support (CSECLS) made this recommendations to guide clinical ECMO application in the patients with NCP.","Zhonghua Jie He He Hu Xi Za Zhi","32035430"],"abstract":["Along with the sharp increase of confirmed cases novel coronavirus infection, more critically ill cases require extracorporeal membrane oxygenation (ECMO) support. Based on the clinical data of novel coronavirus pneumonia (NCP), as well as the dada from previous clinical studies and the recommendations from the Extracorporeal Life Support Organization (ELSO), the committee board of the Chinese Society of Extracorporeal Life Support (CSECLS) made this recommendations to guide clinical ECMO application in the patients with NCP."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-02-10T11:00:00Z","year":2020,"_id":"32035430","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0009","keywords":["Extracorporeal Life Support","Extracorporeal membrane oxygenation","Indication","Novel coronavirus pneumonia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352134715834368,"score":418.10284},{"pmid":32219882,"title":"Controversial treatments: an updated understanding of the Coronavirus Disease 2019.","text":["Controversial treatments: an updated understanding of the Coronavirus Disease 2019.","An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system (ALS) and extracorporeal membrane oxygenation (ECMO), based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong","32219882"],"abstract":["An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system (ALS) and extracorporeal membrane oxygenation (ECMO), based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219882","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25788","keywords":["COVID-19","SARS-CoV-2","coronavirus","literature review","pneumonia","treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"e_drugs":["Ribavirin","Chloroquine"],"_version_":1663352135074447360,"score":369.42032},{"pmid":32087621,"title":"[The keypoints in treatment of the critical novel coronavirus pneumonia patient].","text":["[The keypoints in treatment of the critical novel coronavirus pneumonia patient].","The novel coronavirus pneumonia (new coronavirus pneumonia) (NCP) has been prevalent in Wuhan and spread rapidly to all of our country. Some cases can develop into ARDS, or even death. We will share the treatment experience of severe NCP with the first-line treatment experience. The best respiratory support mode should be selected, but the timing of intubation and protection during intubation are two difficulties; patients with high level peep and poor effect in prone position can be given ECMO support. For NCP patients with mechanical ventilation, reasonable sedation and analgesia strategies should be formulated; delirium should not be ignored. In addition, there is up regulation of inflammatory factors in patients with severe NCP, but the effect of renal replacement therapy needs to be further confirmed by clinical research.","Zhonghua Jie He He Hu Xi Za Zhi","Qiu, H B","Li, X Y","Du, B","Kang, H Y J","Wang, Y S","Wang, F","Sun, B","Tong, Z H","32087621"],"abstract":["The novel coronavirus pneumonia (new coronavirus pneumonia) (NCP) has been prevalent in Wuhan and spread rapidly to all of our country. Some cases can develop into ARDS, or even death. We will share the treatment experience of severe NCP with the first-line treatment experience. The best respiratory support mode should be selected, but the timing of intubation and protection during intubation are two difficulties; patients with high level peep and poor effect in prone position can be given ECMO support. For NCP patients with mechanical ventilation, reasonable sedation and analgesia strategies should be formulated; delirium should not be ignored. In addition, there is up regulation of inflammatory factors in patients with severe NCP, but the effect of renal replacement therapy needs to be further confirmed by clinical research."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Qiu, H B","Li, X Y","Du, B","Kang, H Y J","Wang, Y S","Wang, F","Sun, B","Tong, Z H"],"date":"2020-02-24T11:00:00Z","year":2020,"_id":"32087621","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200222-00151","keywords":["Acute respiratory distress syndrome (ARDS)","Delirium","Mechanical ventilation","Novel coronavirus pneumonia (NCP)","Renal replacement therapy","Sedation and analgesia"],"source":"PubMed","locations":["analgesia","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352134533382144,"score":332.61798}]}